Drug-Coated Balloons vs. Conventional Angioplasty Below the Knee

This meta-analysis is an update on the role of drug-coated balloons in the treatment of infrapopliteal arterial disease, a difficult pathology for all strategies.

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

The primary endpoint of this meta-analysis was treated lower limb salvage at 12 months. The secondary endpoints included survival at 12 months, amputation free survival, restenosis, and target lesion repeat revascularization rate.

This analysis included 10 studies and a total of 1593 patients, even though study quality was moderate to low, according to the standards.

The treated limb salvage rate was 94% with drug-coated balloons vs. 95.7% with conventional angioplasty, which is not a significant difference.


Read also: Crest-2 Registry: Carotid PCI Presents Low Rates of Death and Stroke.


The survival rate at one year was 89.8% vs. 92.9%, which is not a significant difference either.

An analysis of the 4 most uniform studies showed a 32.9% rate of restenosis with drug-coated balloons vs. a 62% rate with conventional angioplasty. This difference seems significant, but there is great dispersion in the confidence interval (odds ratio [OR]: 2.87; 95% confidence interval [CI]: 0.83 to 9.92).

The amputation free survival rate was 82.5% with drug-coated balloons vs. 88.7% with conventional angioplasty (OR: 0.79; 95% CI: 0.23 to 2.75).


Read also: How Much Should We Exercises to Reduce Mortality?


There were no significant differences in any of the studied endpoints.

Conclusion

Based on this systematic review and meta-analysis, there are no significant differences in terms of lower limb salvage, survival, restenosis, target lesion revascularization, or amputation free survival between angioplasty with drug-coated balloons and conventional angioplasty in infrapopliteal arterial disease.

Original Title: Drug Coated Balloon Angioplasty vs. Standard Percutaneous Transluminal Angioplasty in Below the Knee Peripheral Arterial Disease: A Systematic Review and Meta-Analysis.

Reference: Jetty Ipema et al. Eur J Vasc Endovasc Surg, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....